Related Experiment Video
Updated: May 24, 2025
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
16.5K
Perceptions and Use of Germline Genetic Testing Among Patients With Prostate Cancer.
Laura B Beidler1, Kimberly Zayhowski2, Mary Nahorniak3
1Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Lebanon, NH.
JCO Oncology Practice
|March 3, 2025
Summary
Many prostate cancer patients underutilize germline genetic testing due to perceived low priority and treatment burden. Improving communication about the individual and family benefits of genetic testing is crucial for increasing uptake.
Area of Science:
- Oncology
- Genetics
- Health Services Research
Background:
- Germline genetic testing is underutilized in prostate cancer care despite patient eligibility.
- Understanding patient decision-making is key to improving testing rates.
Purpose of the Study:
- To explore patient perceptions and decision-making processes regarding germline genetic testing for prostate cancer.
- To identify barriers and facilitators to genetic testing uptake in this population.
Main Methods:
- Qualitative interview study with prostate cancer patients referred for genetic testing.
- Interviews conducted in participants' native languages via telephone.
- Thematic analysis of interview data and medical records to identify decision-making factors.
Main Results:
- Thirty-three patients participated; 24 had undergone genetic testing (discrepancies with self-report noted).
- Key themes influencing decisions included family value, personal utility, information preferences, and testing priority.
- Cancer treatment burden often led to delayed or declined genetic testing.
Conclusions:
- Opportunities exist to enhance communication regarding the purpose, value, and utility of genetic testing.
- Discussions should emphasize both individual benefits and implications for familial cascade testing in prostate cancer patients.
